Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older-Reference-Cited by-同舟云学术

Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

Published:2023-09-27 Issue:10 Volume:12 Page:2367-2386
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Neveu David,Mallett Moore Tamala,Zambrano Betzana,Chen Aiying,Kürzinger Marie-Laure,Marcelon Lydie,Singh Dhingra Mandeep

Funder

Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-023-00864-4.pdf

Reference48 articles.

1. Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321.

2. Mbaeyi S, Duffy J, McNamara LA. Meningococcal disease. Centres for Disease Control and Prevention (CDC); 2021.

3. Centers for Disease Control and Prevention. Surveillance. Antibiotic-resistant Neisseria meningitidis serogroup Y2019.

4. Krone M, Gray S, Abad R, Skoczynska A, Stefanelli P, van der Ende A, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24(14):1800245.

5. Public Health England. Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2016/2017. Health Protection Report (2017). 2018.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study;Infectious Diseases and Therapy;2024-07-02